GLPG
Price
$33.04
Change
-$0.50 (-1.49%)
Updated
Sep 24 closing price
Capitalization
2.23B
41 days until earnings call
NTLA
Price
$17.76
Change
+$0.68 (+3.98%)
Updated
Sep 24 closing price
Capitalization
1.91B
42 days until earnings call
Interact to see
Advertisement

GLPG vs NTLA

Header iconGLPG vs NTLA Comparison
Open Charts GLPG vs NTLABanner chart's image
Galapagos
Price$33.04
Change-$0.50 (-1.49%)
Volume$123.26K
Capitalization2.23B
Intellia Therapeutics
Price$17.76
Change+$0.68 (+3.98%)
Volume$7.48M
Capitalization1.91B
GLPG vs NTLA Comparison Chart in %
Loading...
GLPG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLPG vs. NTLA commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLPG is a Buy and NTLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (GLPG: $33.04 vs. NTLA: $17.76)
Brand notoriety: GLPG and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLPG: 43% vs. NTLA: 138%
Market capitalization -- GLPG: $2.23B vs. NTLA: $1.91B
GLPG [@Biotechnology] is valued at $2.23B. NTLA’s [@Biotechnology] market capitalization is $1.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $96.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLPG’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • GLPG’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than GLPG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLPG’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • GLPG’s TA Score: 4 bullish, 4 bearish.
  • NTLA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than GLPG.

Price Growth

GLPG (@Biotechnology) experienced а +2.42% price change this week, while NTLA (@Biotechnology) price change was +43.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.75%. For the same industry, the average monthly price growth was +8.46%, and the average quarterly price growth was +51.67%.

Reported Earning Dates

GLPG is expected to report earnings on Nov 05, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLPG($2.23B) has a higher market cap than NTLA($1.91B). NTLA YTD gains are higher at: 52.316 vs. GLPG (20.145). GLPG has higher annual earnings (EBITDA): -225.76M vs. NTLA (-501.87M). GLPG has more cash in the bank: 3.09B vs. NTLA (460M). GLPG has less debt than NTLA: GLPG (8.44M) vs NTLA (103M). GLPG has higher revenues than NTLA: GLPG (276M) vs NTLA (52.9M).
GLPGNTLAGLPG / NTLA
Capitalization2.23B1.91B117%
EBITDA-225.76M-501.87M45%
Gain YTD20.14552.31639%
P/E Ratio54.80N/A-
Revenue276M52.9M522%
Total Cash3.09B460M672%
Total Debt8.44M103M8%
FUNDAMENTALS RATINGS
GLPG vs NTLA: Fundamental Ratings
GLPG
NTLA
OUTLOOK RATING
1..100
8120
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
4536
P/E GROWTH RATING
1..100
53100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for GLPG (70). This means that NTLA’s stock grew somewhat faster than GLPG’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GLPG (100). This means that NTLA’s stock grew similarly to GLPG’s over the last 12 months.

GLPG's SMR Rating (95) in the Biotechnology industry is in the same range as NTLA (98). This means that GLPG’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Price Growth Rating (36) in the Biotechnology industry is in the same range as GLPG (45). This means that NTLA’s stock grew similarly to GLPG’s over the last 12 months.

GLPG's P/E Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that GLPG’s stock grew somewhat faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLPGNTLA
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 7 days ago
60%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
77%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
GLPG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SWLVX15.87-0.03
-0.19%
Schwab ® US Large-Cap Value Index
ALCCX21.63-0.07
-0.32%
Alger Capital Appreciation C
PAIGX23.01-0.11
-0.48%
T. Rowe Price International Value Eq Adv
LGCRX19.50-0.12
-0.61%
Lord Abbett Global Equity R3
VYRDX13.76-0.10
-0.72%
VY® Columbia Small Cap Value II R6

GLPG and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLPG has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if GLPG jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLPG
1D Price
Change %
GLPG100%
-1.49%
BEAM - GLPG
40%
Loosely correlated
-0.59%
NTLA - GLPG
39%
Loosely correlated
+3.98%
RGNX - GLPG
39%
Loosely correlated
+6.83%
IPSC - GLPG
35%
Loosely correlated
-0.19%
CRSP - GLPG
35%
Loosely correlated
+0.48%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NTLA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+3.98%
CRSP - NTLA
63%
Loosely correlated
+0.48%
BEAM - NTLA
63%
Loosely correlated
-0.59%
RXRX - NTLA
53%
Loosely correlated
+1.46%
ABCL - NTLA
50%
Loosely correlated
-2.65%
ALLO - NTLA
50%
Loosely correlated
+5.13%
More